ARTICLE | Finance
Potentiator potential
Why Pfizer Venture Investments led Effector's $38.6M series C
July 29, 2017 2:48 AM UTC
Preclinical data showing how eFT508 could fit into checkpoint inhibitor cocktails helped Effector Therapeutics Inc. snag Pfizer Inc. (NYSE:PFE) as both a development partner and an investor.
On July 24, Effector closed a $19.3 million first tranche of a $38.6 million series C round led by new investor Pfizer Venture Investments. The second and final tranche is slated to close in 2018. The trigger is undisclosed...
BCIQ Company Profiles